User profiles for Keith SK Leung
 | Keith Sai Kit LeungAcademic Foundation Doctor, Hull University Teaching Hospitals NHS Trust Verified email at nhs.net Cited by 839 |
Barriers and shortcomings in access to cardiovascular management and prevention for familial hypercholesterolemia during the COVID‐19 pandemic
Familial hypercholesterolemia (FH) is a hereditary condition caused by mutations in the
lipid pathway. The goal in managing FH is to reduce circulating low‐density lipoprotein …
lipid pathway. The goal in managing FH is to reduce circulating low‐density lipoprotein …
Comparative effects of sodium glucose cotransporter 2 (SGLT2) inhibitors and dipeptidyl peptidase-4 (DPP4) inhibitors on new-onset atrial fibrillation and stroke …
Background SGLT2I and DPP4I are medications prescribed for type 2 diabetes mellitus
patients. However, there are few population-based studies comparing their effects on incident …
patients. However, there are few population-based studies comparing their effects on incident …
[HTML][HTML] SOX9 governs differentiation stage-specific gene expression in growth plate chondrocytes via direct concomitant transactivation and repression
Cartilage and endochondral bone development require SOX9 activity to regulate
chondrogenesis, chondrocyte proliferation, and transition to a non-mitotic hypertrophic state. The …
chondrogenesis, chondrocyte proliferation, and transition to a non-mitotic hypertrophic state. The …
[HTML][HTML] Sodium-glucose cotransporter 2 (SGLT2) inhibitors vs. dipeptidyl peptidase-4 (DPP4) inhibitors for new-onset dementia: a propensity score-matched …
Introduction: The effects of sodium-glucose cotransporter 2 inhibitors (SGLT2I) and dipeptidyl
peptidase-4 inhibitors (DPP4I) on new-onset cognitive dysfunction in type 2 diabetes …
peptidase-4 inhibitors (DPP4I) on new-onset cognitive dysfunction in type 2 diabetes …
SOX9 and SOX10 control fluid homeostasis in the inner ear for hearing through independent and cooperative mechanisms
…, KC Chu, TYK Au, KKH Leung… - Proceedings of the …, 2022 - National Acad Sciences
The in vivo mechanisms underlying dominant syndromes caused by mutations in SRY-Box
Transcription Factor 9 (SOX9) and SOX10 (SOXE) transcription factors, when they either are …
Transcription Factor 9 (SOX9) and SOX10 (SOXE) transcription factors, when they either are …
Phosphorylation stabilized TET1 acts as an oncoprotein and therapeutic target in B cell acute lymphoblastic leukemia
…, D Wu, Z Gu, VN Ngo, X He, J Chao, K Leung… - Science translational …, 2023 - science.org
Although the overall survival rate of B cell acute lymphoblastic leukemia (B-ALL) in
childhood is more than 80%, it is merely 30% in refractory/relapsed and adult patients with B-ALL. …
childhood is more than 80%, it is merely 30% in refractory/relapsed and adult patients with B-ALL. …
TET2-mediated mRNA demethylation regulates leukemia stem cell homing and self-renewal
TET2 is recurrently mutated in acute myeloid leukemia (AML) and its deficiency promotes
leukemogenesis (driven by aggressive oncogenic mutations) and enhances leukemia stem …
leukemogenesis (driven by aggressive oncogenic mutations) and enhances leukemia stem …
Triglyceride Glucose Index Predicts Risk of Adverse Cardio-metabolic and Mortality Outcomes Among Chinese Adults: A Territory-Wide Longitudinal Study
Background The triglyceride glucose (TyG) index has been proposed to be a surrogate of
insulin resistance. In the study, we aimed to examine the relationship between TyG index and …
insulin resistance. In the study, we aimed to examine the relationship between TyG index and …
[HTML][HTML] Novel mechanisms in heart failure with preserved, midrange, and reduced ejection fraction
Heart failure (HF) represents a major epidemic with high morbidity and mortality rates, imposing
a significant burden on healthcare systems worldwide (Savarese and Lund, 2017). HF …
a significant burden on healthcare systems worldwide (Savarese and Lund, 2017). HF …
A phase 2 study of lenalidomide, rituximab, cyclophosphamide, and dexamethasone (LR‐CD) for untreated low‐grade non‐Hodgkin lymphoma requiring therapy
…, JF Leis, JR Mikhael, A Keith Stewart… - American journal of …, 2017 - Wiley Online Library
Patients with indolent non‐Hodgkin lymphoma (NHL) have multiple treatment options yet
there is no consensus as to the best initial therapy. Lenalidomide, an immunomodulatory agent…
there is no consensus as to the best initial therapy. Lenalidomide, an immunomodulatory agent…
